Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRAVO extension study of oral laquinimod in relapsing multiple sclerosis
2009-015815-42Phase 3Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of laquinimod in relapsing-remitting multiple sclerosis (RRMS) and multiple sclerosis (MS), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Long-term safety, Long-term tolerability and 2 more. Started Feb 2010; status: terminated.
02
Drugs
laquinimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)multiple sclerosis (MS)
Beyond the preview
Go deeper on 2009-015815-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015815-42.